Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Shares of Astrazeneca Pharma India Ltd ended at ₹8,984.50, down by ₹32.00, or 0.35%, on the BSE.
